News & Media

Proteomics and Dimerix partner to improve the treatment of kidney disease

Written by Proteomics | Dec 13, 2017 7:00:00 PM

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a leader in providing predictive diagnostics, is pleased to announce that it has partnered with innovative drug developer Dimerix Limited (ASX:DXB) to improve the treatment of chronic kidney disease (CKD).

Media Release